Title

Sponsor

A randomized, double-blind, placebo controlled, single-dose study to assess the initial efficacy of canakinumab (ACZ885) with respect to the adapted ACR Pediatric 30 criteria in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestation

 Novartis

A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations

 Novartis

An open label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestation

 Novartis

A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis

 Hoffman-La Roche, LTD

 Compassionate Use Study of Adalimumab in Children 2 to <4 Years Old or Age 4 and Above Weighing Less than 15 kg with Active Juvenile Idiopathic Arthritis (JIA)

 Abbott

 A Long-term, Multicenter, Longitudinal Post-marketing, Observational Registry of Humira (adalimumab) in Children with Active Juvneile Idiopathic Arthritis (JIA)

 Abbott

SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs

 Pfizer

A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis, With an Open-Label Extension to Examine the Long Term Use of Tocilizumab

 Hoffman- La Roche, LTD

 A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)

 Bristol-Myers Squibb

 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis

 Abbott

For a comprehensive list of all rheumatology studies, click here